人组织型激肽释放酶6在卵巢上皮性肿瘤中的表达及其与临床病理特征和预后的关系

Correlation of hK6 expression with clinicopathological features and prognosis in epitheliail ovarian cancer

目的探讨人组织型激肽释放酶6（hK6）在卵巢肿瘤组织中的表达与临床病理特征和预后的关系。方法通过免疫组化SP法检测hK6在19例良性卵巢上皮性肿瘤、11例交界性卵巢上皮肿瘤和45例卵巢癌中的表达，分析其表达与卵巢癌患者年龄、原发肿瘤大小、肿瘤组织学类型、分化程度、临床分期和淋巴结转移等临床病理特征和患者预后的关系，并探讨其临床意义。结果hK6在良性、交界性和恶性卵巢肿瘤组织中的阳性表达率分别为15．8％、27．3％和60．0％，卵巢癌组织中的hK6阳性表达率明显高于良性和交界性肿瘤（P〈0．01）。hK6的阳性表达与患者年龄、原发肿瘤大小以及肿瘤组织学类型无关，而与肿瘤组织分化程度、临床分期及淋巴结转移密切相关。hK6在中、低分化卵巢癌组织中的表达率（68．4％）明显高于高分化者（14．3％，P〈0．05），在Ⅲ期卵巢癌组织中的阳性表达率（76．7％）显著高于Ⅰ-Ⅱ期（26．7％，P〈0．01），在有淋巴结转移者的卵巢癌组织中的阳性表达率（77．8％）明显高于无淋巴结转移者（33．3％，P〈0．01），在术后3年内复发、转移、死亡患者的卵巢癌组织中的阳性表达率（75．0％）高于术后3年内病情稳定者（42．9％，P〈0．05）。结论hK6在卵巢癌组织中的表达明显高于良性和交界性卵巢肿瘤组织，且在临床晚期、组织分化差、有淋巴结转移、预后差的卵巢癌中高表达，提示hK6可能是一种新的反映卵巢癌恶性程度和预后的肿瘤标志物。

Objective To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopatbological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer. Methods The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer. Results The expression of hK6 in ovarian cancer tissues （60.0%） was significantly higher than that in the benign （ 15.8% ） and borderline （27.3%） ovarian neoplasm tissues （ P 〈 0.01 ）. The expression of hK6 in higher-grade ovarian cancer tissues （ 68.4% ） was higher than that in low-grade ones （ 14.3 % , P 〈 0.05）. The expression of hK6 in/ate-stage （ stageⅢ, 76.7% ） was significantly higher than that in early-stage （stage Ⅰ or Ⅱ ,26.7% ,P 〈 0.01 ）. The expression of hK6 was significantly higher in patients with lymph node metastasis （77.8%） than that in patients without （33.3% ,P 〈0.01 ）. The expression of hK6 in the cancer tissues in the patients died, or with reccurence or metastasis within 3 years after surgery was higher （75.0%） than that in the patients with stable disease （42.9% , P 〈 0.05 ）. Conclusion The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis, hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.